Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CAMP4 Therapeutics Corporation - Common Stock (NQ:CAMP)

3.875 -0.045 (-1.15%)
Streaming Delayed Price Updated: 3:41 PM EDT, Sep 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 61,789
Open 3.860
Bid (Size) 3.850 (500)
Ask (Size) 3.890 (1,000)
Prev. Close 3.920
Today's Range 3.730 - 3.950
52wk Range 2.850 - 7.750
Shares Outstanding 20,161,073
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002 ↗
CAMP4 Therapeutics (NASDAQ:CAMP) said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results... 
Via MarketBeat
News headline image
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
From CAMP4 Therapeutics
Via GlobeNewswire

Performance

YTD
-35.4%
-35.4%
1 Month
-6.6%
-6.6%
3 Month
-12.7%
-12.7%
6 Month
-3.1%
-3.1%
1 Year
+26.2%
+26.2%

More News

Read More
News headline image
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 to Participate in Upcoming Investor Conferences
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer ↗
Via The Motley Fool
Topics Initial Public Offering
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Appoints Michael MacLean to its Board of Directors
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
Via The Motley Fool
News headline image
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗
Via The Motley Fool
News headline image
CAMP4 to Participate in Upcoming Investor Conferences
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is CAMP4 Therapeutics Corporation - Common Stock publicly traded?
Yes, CAMP4 Therapeutics Corporation - Common Stock is publicly traded.
What exchange does CAMP4 Therapeutics Corporation - Common Stock trade on?
CAMP4 Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for CAMP4 Therapeutics Corporation - Common Stock?
The ticker symbol for CAMP4 Therapeutics Corporation - Common Stock is CAMP on the Nasdaq Stock Market
What is the current price of CAMP4 Therapeutics Corporation - Common Stock?
The current price of CAMP4 Therapeutics Corporation - Common Stock is 3.875
When was CAMP4 Therapeutics Corporation - Common Stock last traded?
The last trade of CAMP4 Therapeutics Corporation - Common Stock was at 09/28/26 03:41 PM ET
What is the market capitalization of CAMP4 Therapeutics Corporation - Common Stock?
The market capitalization of CAMP4 Therapeutics Corporation - Common Stock is 78.12M
How many shares of CAMP4 Therapeutics Corporation - Common Stock are outstanding?
CAMP4 Therapeutics Corporation - Common Stock has 78M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.